Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
US10610563B2 · kind B2 · utility
0Cited by
1References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 24, 2015 |
| Grant date | Apr 7, 2020 |
| Priority date | — |
| Expiry date | Nov 24, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention discloses a method of treating, preventing or ameliorating tumor or symptoms resulting from defective neurofibromatosis type-2 gene in a subject by administering to the subject a therapeutically effective amount of a ubiquitin-proteasome system inhibitor which inhibits or slows the growth of neurofibromatosis type-2-deficient tumor or associated symptoms. The invention also includes methods of diagnosis and screening of patients for neurofibromatosis type-2 and mesothelioma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.